A Review on Anticancer Potential and Structure-Activity Relationships (SAR) of Novel EGFR/HER2 Inhibitors

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Human Epidermal Growth Receptors (HER), including EGFR/HER1, HER2, HER3, and HER4, are key regulators of cell signaling pathways.
• Overexpression of HER receptors is implicated in the development and progression of various cancers.
• Current EGFR/HER2 dual inhibitors face challenges with selectivity, specificity, adverse effects, and drug resistance.

Purpose of the Study:

• To identify and develop novel therapeutic molecules targeting both EGFR and HER2 for cancer treatment.
• To explore different structural classes of potential EGFR/HER2 dual inhibitors.
• To provide insights for designing next-generation EGFR/HER2 dual inhibitors with improved therapeutic potential.

Main Methods:

• Review and analysis of existing literature on EGFR/HER2 dual inhibitors.
• Focus on Structure-Activity Relationships (SAR) of different chemical scaffolds.
• Inclusion of data from clinical trials and patent filings.
• Molecular docking studies to assess binding affinities of potent compounds.

Main Results:

• Highlighting various structural classes of EGFR/HER2 dual inhibitors, including pyrimidine, quinazoline, pyridine, benzimidazole, and quinoline derivatives.
• Discussing the importance of SAR, clinical data, and patent landscape for lead compound development.
• Identifying key challenges in developing precise and less toxic EGFR/HER2 dual inhibitors.

Conclusions:

• The development of novel EGFR/HER2 dual inhibitors is essential to overcome limitations of existing therapies.
• Medicinal and organic chemists are actively designing new molecules with improved precision and reduced toxicity.
• Further research into Structure-Activity Relationships and molecular interactions will guide the discovery of potent EGFR/HER2 dual inhibitors for breast and lung malignancies.